Placebo News and Research

RSS

Lenvatinib trial offers hope for thyroid cancer patients

A new targeted therapy called lenvatinib has been shown to improve progression-free survival among patients with advanced thyroid cancer that is not responsive to iodine-131.

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

$Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer$

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

12 Feb 2015

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

Continuing its efforts to fight for settlements that are fair to consumers and mandate real changes in deceptive marketing, advocacy group truthinadvertising.org (TINA.org) has filed an objection in a proposed class-action settlement involving the brand-name glucosamine supplement, Wellesse®. Sold at retailers nationwide, the supplement is advertised as a joint pain remedy to ease pain and even rebuild cartilage.

12 Feb 2015

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

AbbVie (NYSE: ABBV) submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) seeking approval for the company's investigational, all-oral, ribavirin (RBV) and interferon (IFN)-free, 12-week, two direct-acting antiviral treatment of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r), dosed once daily.

12 Feb 2015

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.

11 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

Experimental Ebola virus medication shows promise in monkeys

An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration with Sarepta Therapeutics, Inc.

10 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Abiraterone drug improves survival in prostate cancer patients when given before chemotherapy

Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown.

9 Feb 2015

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.

8 Feb 2015

Electronic cigarettes and smoking cessation: an interview with Professor Peter Hajek

The electronic cigarette has been invented by Chinese pharmacist Hon Lik in 2003. The rise in electronic cigarettes (EC) popularity was initially a grass root phenomenon. EC are estimated to be at least 95% safer than cigarettes and they appeal to smokers who cannot or do not want to stop smoking, but who want to reduce the risks smoking poses to their health.

5 Feb 2015

Study focuses on two natural approaches to preventing breast cancer

Preventing cancer requires intimate knowledge of how cancer starts, what causes it to grow and flourish, and how to stop it in its tracks. Sometimes this comes in the form of a vaccine (the HPV vaccine for cervical and head and neck cancers), a screening (a colonoscopy for colorectal cancer) or a blood test (the PSA level test for prostate cancer).

5 Feb 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol.

4 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Study looks at effect of probiotic capsule intervention on metabolic health among women with GDM

In a study to be presented on Feb. 5 in an oral concurrent session at 1:15 p.m. PST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in San Diego, researchers will report on the effect of a probiotic capsule intervention on maternal metabolic parameters and pregnancy outcomes among women with gestational diabetes.

3 Feb 2015

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Australian biopharmaceutical company Immuron Limited has today announced a significant milestone in its Phase 2 clinical trial for non-alcoholic steatohepatitis (NASH) with the recruitment of its first two patients at Duke University in the United States. It is expected that further recruitment at Duke and other sites in the US and Australia will follow in early course.

3 Feb 2015

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

A large clinical trial to assess the safety and efficacy of two experimental vaccines to prevent Ebola virus infection is now open to volunteers in Liberia. The trial is being led by a recently formed Liberia-U.S. clinical research partnership and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Feb 2015

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Theravance Biopharma, Inc. and Mylan Inc. today announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

2 Feb 2015

Placebo News and Research

Lenvatinib trial offers hope for thyroid cancer patients

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Lenvatinib therapy improves survival in patients with advanced radioiodine-refractory thyroid cancer

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

AbbVie submits NDA in Japan for investigational, all-oral treatment of patients with chronic HCV infection

Researchers close to novel therapy to treat levodopa-induced dyskinesia

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Experimental Ebola virus medication shows promise in monkeys

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Abiraterone drug improves survival in prostate cancer patients when given before chemotherapy

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Electronic cigarettes and smoking cessation: an interview with Professor Peter Hajek

Study focuses on two natural approaches to preventing breast cancer

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Study looks at effect of probiotic capsule intervention on metabolic health among women with GDM

Immuron begins patient recruitment for Phase 2 clinical trial of IMM-124E NASH drug candidate

Large clinical trial to assess safety, efficacy of two experimental Ebola vaccines opens in Liberia

Theravance Biopharma, Mylan partner to develop and commercialize TD-4208 for COPD treatment

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News